Starling Oncology Inc(TOI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.38 | Insider Own | 36.51% | Shs Outstand | 100.0M | Perf Week | -1.16% |
| Market Cap | 0.51B | Forward P/E | - | EPS next Y | 81.88% | Insider Trans | 1.77% | Shs Float | 63.5M | Perf Month | -2.84% |
| Enterprise Value | 0.59B | PEG | - | EPS next Q | -0.06 | Inst Own | 35.31% | Short Float | 11.46% | Perf Quarter | 26.67% |
| Income | -0.04B | P/S | 0.94 | EPS this Y | 74.44% | Inst Trans | 0.77% | Short Ratio | 3.79 | Perf Half Y | 89.3% |
| Sales | 0.55B | P/B | - | EPS next 5Y | - | ROA | -21.84% | Short Interest | 7.27M | Perf YTD | 44.1% |
| Book/sh | -0.16 | P/C | 16.94 | EPS past 3/5Y | -37.23% -17.58% | ROE | -3407.86% | 52W High | -23.09% ($6.67) | Perf Year | 37.53% |
| Cash/sh | 0.3 | P/FCF | - | Sales past 3/5Y | 25.81% 21.8% | ROIC | -44.7% | 52W Low | 121.12% ($2.32) | Perf 3Y | 440% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 46.1% | Gross Margin | 13.88% | Volatility(W/M) | 7.53% 7.71% | Perf 5Y | -48.18% |
| Dividend TTM | - | EV/Sales | 1.08 | Sales Y/Y TTM | 35.37% | Oper. Margin | -5.99% | ATR (14) | 0.38 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.17 | EPS Q/Q | 90.12% | Profit Margin | -6.65% | RSI (14) | 48.47 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.47 | Sales Q/Q | 41.22% | SMA20 | -5.2% ($5.41) | Beta | 0.41 | Target Price | $8.4 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/6 | SMA50 | -0.62% ($5.16) | Rel Volume | 0.66 | Prev Close | $4.86 |
| Employees | 641 | LT Debt/Eq | - | EPS/Sales Surpr. | 77.14% 3.76% | SMA200 | 32.99% ($3.86) | Avg Volume(3M) | 1.92M | Price | $5.13 |
| IPO | 2020/6/4 | Option/Short | Yes/Yes | Trades | 10294 | Volume | 1,262,010 | Change | 5.56% |
Company
TOI is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🩺 Oncology Institute TOI is a US-based community-focused, value-based oncology care medical group. Through a network of more than 60 clinic locations, it delivers integrated cancer care—including anti-cancer treatment, drug dispensing, and clinical trials—in a community setting, with a focus on expanding access to evidence-based treatment for a large number of patients.
Over the past 1 year, roughly in the middle
23% below its 1-year high.
TOI has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +74.4% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +440.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 35.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
AKRE 0.06%
WAGN 0.05%
CCFE 0.03%
IGGY 0.02%
QINT 0.00%It ranks #4 in the industry
Based on market cap of $513M.
TOI $513M PER -
HCA $92B PER 14.3
THC $21B PER 10.2
EHC $12B PER 19.8
FAQ
What kind of company is TOI?
TOI belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of TOI?
The market cap of TOI is approximately $513M, ranking 3,184 within its sector.
What is the 52-week high and low for TOI?
TOI has recorded a 52-week high of $6.67 and a low of $2.32.
